KR20020084336A - Composition for preventing or treating dementia comprising a curcumin or derivatives thereof - Google Patents

Abstract

PURPOSE: A composition containing curcumin of formula 1 extracted from Curcuma longa L. or derivatives thereof and a pharmaceutically acceptable salt exhibiting excellent prophylactic effect on dementia is provided which can be effectively used in the treatment of dementia. CONSTITUTION: A prophylactic and therapeutic composition for dementia contains 2 to 70% by weight of a Curcuma longa extract, 1 to 10% by weight of edible spirits, 0.5 to 3% by weight of an excipient or diluent, 0.5 to 3% by weight of betacyclodextrin, 0.5 to 5% by weight of a sweetening agent, 0.1 to 1% by weight of a surfactant, 0.5 to 5% by weight of an antioxidant such as vitamin C, vitamin E and a mixture thereof, 0.001 to 1% by weight of a fragrance and 25 to 70% by weight of distilled water.

Description

Composition for preventing or treating dementia comprising curcumin or derivatives thereof

The present invention relates to a composition for the prevention and treatment of dementia, and more particularly, to a composition for the prevention and treatment of dementia comprising curcumin or a derivative thereof as an active ingredient.

Recently, due to the rapid increase in the elderly population, the development of seniledementia associated with aging has become a serious social problem. Despite the high incidence, the disease is currently devoid of significant treatments and preventive agents, causing massive socioeconomic losses.

Geriatric dementia is an age-related mental disorder that is a result of degenerative changes in the brain according to old age. It is mainly caused by the deterioration of intelligence and occurs in the old age of 65 to 70 years. The senile dementia causes significant brain atrophy, and signs such as a decrease in neurons, increased ribovstin in neurons, the appearance of senile spots and thickening of neurofibrillary tangles. In addition, symptoms such as severe forgetfulness, memory impairment, and perceptual depression appear, and judgment or reasoning power decreases, and the power of calculation decreases.

In particular, Alzheimer's disease is one of the most important diseases among senile dementia, and the accumulation of beta amyloid (β-amyloid) in the brain and its neurotoxicity are known as a very important cause of the onset (Selkoe et al . , Annu. Rev. Neurosci ., 17: 489-517, 1994). When the disease occurs, such symptoms as general atrophy of the brain, enlargement of the ventricles, multiple lesions of the nerve fibers and elderly spots, etc. are manifested, and the decline of intellectual functions such as memory, judgment, and speech ability and behavioral disorders appear. In severe cases, it may also be accompanied by psychiatric symptoms such as depression. In addition, Alzheimer's disease is a serious disease in which the above symptoms gradually progress, leading to death 6-8 years after the onset.

Currently, about 3% of the 65-74 year old population, about 19% of the 75-84 year old population, and 50% of the population aged 85 or older are reported to have the disease. Percentages of dementia have been reported, and about 63% have Alzheimer's disease. In particular, the disease, which is rapidly increasing with the increase in the elderly population, is a disease that requires a diversified approach from the patient himself, his family, and medical and social aspects.

In order to prevent and treat Alzheimer's disease, efforts have been made to develop a substance that can block the toxicity of beta amyloid, which is known as a cause of Alzheimer's disease, but there are no effective treatments yet. Therefore, the present inventors have continuously conducted research for effectively preventing and treating dementia and disclosed a dementia treatment agent having a hydroxycinnamic acid derivative of Angelica extract as a composition in Korean Patent Application No. 2000-071673.

On the other hand, Curcuma longa is a tuber of ginger and turmeric or turmeric, which is said to have the effect of promoting the circulation of qi, loosening the lump, nourishing blood and removing blood It is frequently used for the purpose of treating emphysema, bleeding, nasal bleeding, hematuria, hemorrhage, menstruation and jaundice of women.

The present inventors, while studying the extract from the turmeric, the curcumin component of turmeric extract reveals that the structure and efficacy similar to the dimer of ferulic acid (ferulic acid), one of the derivatives of hydroxycinnamic acid, such curcumin The present invention was completed by using as a composition for preventing and treating dementia.

Accordingly, it is an object of the present invention to provide a composition for preventing and treating dementia.

In addition, another object of the present invention to provide a food comprising the composition for preventing and treating dementia as an active ingredient.

Figure 1 shows the result of confirming the presence of curcumin (curcumin) in turmeric extract by HPLC chromatogram.

Figure 2 graphically shows the results of the passive avoidance test in rats to observe the effect of treatment of dementia treatment dementia.

Figure 3 is a graph showing the results of performing a passive avoidance test in rats after administration of curcumin (CUR), the main active ingredient of turmeric extract.

Figure 4 is a graph showing the results of the Y-maze test according to the administration period in order to observe the therapeutic effect of turmeric extract dementia.

Figure 5 is injected with beta amyloid (1-42) to confirm the brain cell protective action of curcumin, the main active ingredient of turmeric extract, 1 day after the mice's cortex (Pyriform cortex) to extract the OX-42 immunity Photo shows the results of chemical staining.

A: control group

B: beta amyloid (1-42) administration group

C: beta amyloid group 30 minutes after curcumin administration

Figure 6 is injected beta amyloid (1-42) to confirm the brain cell protective action of curcumin, the main active ingredient of turmeric extract, and after one day after taking amygdaloid nucleus of the mouse immunity of OX-42 Photo shows the results of chemical staining.

D: control group

E: beta amyloid (1-42) administration group

F: beta amyloid group 30 minutes after curcumin administration

FIG. 7 shows beta amyloid (1-42) alone and curcumin and beta amyloid mixed and administered to confirm the effect of curcumin neuronal cell damage, and the level of lactate dehydrogenase (LDH) secretion. The measurement results are shown graphically.

In order to achieve the above object of the present invention, the present invention provides a composition for preventing and treating dementia comprising curcumin represented by the following formula (1) or a derivative thereof and a pharmaceutically acceptable salt.

Examples of curcumin derivatives represented by Formula 1 include yakuchinone A, yakuchinone B, tetrahydrocurcumin, hydroxycinnamic acid derivatives, and biological materials of these derivatives. Metabolites are included, and hydroxycinnamic acid derivatives include ferullic acid, isoferulic acid, chlorogenic acid and caffeic acid. In vivo metabolites of these derivatives also include demethoxy curcumin and bisdimethoxy curcumin.

In addition, the present invention provides a food for preventing and treating dementia comprising curcumin represented by the formula (1) or derivatives thereof in order to achieve another object of the present invention.

Hereinafter, the present invention will be described in detail.

Curcumin of Formula 1 or derivatives thereof included in the composition for preventing and treating dementia of the present invention may be chemically synthesized or separated from plants, but more preferably separated from plants. Curcumin or derivatives thereof may be separated from plants, such as turmeric, turmeric, horseshoe turmeric, sesame and sprouts, but are not limited thereto. Specifically, it is preferable to be separated from turmeric.

Curcumin of Formula 1 or derivatives thereof may be synthesized according to commonly used chemical methods. The primary reactants of the synthesis process are diketone (2,4-diketone) and aromatic aldehyde, the structural formula of the diketone is H ₂ RC-CO-CH ₂ -CO-CRH ₂ , where R is H or It may be a hydrocarbon group having 1 to 12 carbon atoms selected from alkyl, aryl, aralryl, alkaryl groups and mixtures thereof. In the above diketone is acetylacetone, 2,4-pentanedione (2,4-pentanedione) or 3-substituted-2,4-pentanedione (3-substituted-2,4-pentanedione) and the like May be used, but is not limited thereto, and it is preferable to use 2,4-pentanedione.

Aromatic aldehydes commonly used in the chemical synthesis of curcumin of the present invention include o-vanillin, veratraldehyde, 3-anisaldehyde, and 2-anisaldehyde. 2-anisaldehyde), p-anisaldehyde, 2-hydroxybenzaldehyde, 3-hydroxybenzaldehyde, 4-hydroxybenzaldehyde, 4-hydroxybenzaldehyde (syringaldehyde), 2-hydroxy-5-nitrobenzaldehyde, 3-fluoro-2-methylbenzaldehyde, 3-hydroxy-4-nitro 3-hydroxy-4-nitrobenzaldehyde, 4-hydroxy-3-nitrobenzaldehyde, 2-nitro-5-hydroxybenzaldehyde, 3- Fluoro-4-methoxybenzaldehyde, 2-fluorobenzaldehyde (3-fluorobenzaldehyde), 3-fluorobenzaldehyde (3-flurobenzaldehyde), 4-fluorobenzaldehyde (4-fluorobenzaldehyde), 3-fluoro-2-ethylbenzaldehyde (3-fluoro-2-ethylbenzaldehyde Or 3-fluoro-2-hydroxybenzaldehyde, etc. may be used, but vanillin having the same structure as the basic skeleton structure of curcumin is preferably used.

In addition, the curcumin of the formula (1) or derivatives thereof may be extracted from plants such as turmeric, turmeric, horseshoe turmeric, sesame or sprouts in addition to chemical synthesis, but is preferably extracted from turmeric by conventional methods known in the art. Do. That is, a lower alcohol such as methanol or ethanol, preferably 80% ethanol, is added to the root of turmeric for 15 minutes-48 hours, preferably 30 minutes-12 hours at 5-80 ° C, preferably 30-50 ° C. Extract to obtain turmeric extract. The extract thus obtained contains curcumin, the content of these curcumin may vary depending on the extraction conditions, conditions for cultivation of raw materials and harvest time. As the extraction solvent, an organic solvent such as methanol, acetone, chloroform or methylene chloride may be used, but is not limited thereto. In addition, the extracted turmeric extract may be prepared in powder form or liquid phase.

The turmeric extract and curcumin obtained as described above showed a prophylactic and therapeutic effect on Alzheimer's disease in Alzheimer's disease mouse model in which memory was decreased by directly administering beta amyloid, a dementia-inducing protein, to the ventricles. The model and turmeric extract or curcumin-administered mouse model can be confirmed by performing a passive avoidance test and a Y-maze test. Intraventricular injection of beta amyloid in the present invention is according to the method of Lauren et al . (Laursen & Belknap, J. Pharmacol . Methods, 16: 355-357, 1986), the manual evacuation test is a method of Song et al ., (Song et al ., J. Neurochem ., 71: 875-878, 1998), and the Y-maze test was performed according to the method of Starter et al . (Starter et al ., Psychopharmacology , 94: 491-495, 1988).

In one embodiment of the present invention, to confirm the dementia preventive effect of turmeric extract and curcumin was carried out experiments to confirm the protective effect of the turmeric extract and curcumin brain cells. The method commonly used in the art may be used to confirm the brain cell protective action, but in the present invention, the immune cell chemical staining method of 0X-42 was used. The method is a method for staining the microglia (microglia) that is increased when inflammation in the brain due to various causes, such as virus infiltration using an antibody against OX-42, a marker of microglia.

In addition, in another embodiment of the present invention in order to confirm the dementia preventive effect of turmeric extract and curcumin was confirmed the neuronal damage prevention effect of turmeric extract and curcumin. In order to confirm the effect of preventing nerve cell damage, a method of measuring the secretion of cholineacetyl transferase (ChAT) or lactate dehydrogenase, which is a brain neurotransmitter by beta amyloid, may be used. In the present invention was confirmed by measuring the degree of secretion of lactic acid dehydrogenase. Lactate dehydrogenase is one of the biochemical markers associated with neuronal growth.

On the other hand, the compositions of the present invention, tablets, pills, powders, sachets, elixirs using methods known in the art to provide rapid, sustained or delayed release of the active ingredient after administration to a mammal. It may be formulated in the form of (elixir), suspensions, emulsions, solutions, syrups, aerosols, soft or hard capsules, sterile injection solutions and sterile injection powders, but is preferably formulated in the form of hard capsules or suspensions.

Hard capsules comprising curcumin or derivatives thereof of the present invention may be formulated from a composition consisting of 30-70% by weight turmeric extract, 3-30% by weight antioxidant and 20-40% by weight excipient or diluent.

Meanwhile, the composition for preventing and treating dementia of the present invention is 2-70% by weight of turmeric extract powder, 1-10% by weight of edible alcohol, 0.5-3% by weight of excipient or diluent, 0.5-3% by weight of betacyclodextrin, and 0.5-% of sweetener. It may be formulated in the form of a suspension from a composition consisting of 5% by weight, 0.1-1% by weight surfactant, 0.5-5% by weight antioxidant, 0.001-1% by weight fragrance and 25-70% by weight distilled water.

The antioxidant may be used without limitation as long as it is vitamins, but it is preferable to use vitamin C or vitamin E, and specifically, 3% by weight is preferably added.

In addition, the excipient or diluent may be lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphonate, calcium silicate, cellulose, methylcellulose, Ethyl cellulose, microcrystalline cellulose, carboxymethyl cellulose, hydroxypropyl methyl cellulose, hydroxypropyl methyl cellulose phthalate, polyvinylpyrrolidone, water, methyl hydroxybenzoate, propyl hydroxy benzoate, talc, magnesium stearate, hard It can be used selected from the group consisting of silicic anhydride, mineral oil and the like, it is preferable to add 15-55% by weight, specifically 30% by weight of microcrystalline cellulose.

The composition of the present invention may further include fillers, anti-coagulants, lubricants, wetting agents, fragrances, emulsifiers and preservatives.

The pharmaceutical compositions according to the invention formulated in the form of hard capsules or suspensions can be administered via several routes, including oral, transdermal, subcutaneous, intravenous and intramuscular, with a typical daily dosage of curcumin derivatives of 0.1-50 mg. / kg x body weight, can be administered once or divided into several. In addition, turmeric extract can be administered within the range of 1-500 mg / kg x body weight. However, the actual dosage of the pharmaceutical composition is not limited thereto, and may be changed by various related factors such as the route of administration, the age, sex, weight, and severity of the patient.

On the other hand, curcumin or derivatives thereof and turmeric extract containing them may be added to food or beverages for the purpose of preventing and treating dementia, and may be added to various foods, beverages, gums, teas, vitamin complexes and health supplements. have.

Hereinafter, the present invention will be described in detail by way of examples.

However, the following examples are only for exemplifying the present invention, and the contents of the present invention are not limited to the following reference examples and examples.

In the following examples, intraventricular injection, manual avoidance test, and Y-maze test of beta amyloid were performed according to the following method.

1) Intraventricular injection of beta amyloid (1-42)

A 26 gauge needle was inserted into a 50 μl Hamilton syringe, and an injection tip of 2.4 mm was inserted into the bregma of the mouse, and 1.85 μg / 5 μl of beta amyloid (1-42) was injected into the ventricle. After injection into the ventricle, manual evasion was performed 1-2 days later (day 1: training, day 2: test), and 3-4 days later by Y-maze (day 3: training, day 4: inspection).

2) Passive avoidance test

The manual evasion test evaluated learning and memory.

A manual evacuation box was used for the inspection, which consisted of a brightly lit room and a dark room, and the floor was provided with an electric shock. First, the mice were placed in a bright room, and as soon as the mice entered the dark room, they were subjected to electric shock for 1 second at 0.25 mA. 24 hours after the training, the mice were placed in a bright room and the time to enter the dark room was measured as a passive avoidance reaction time. The maximum time limit was 300 seconds. If the user did not enter the dark room for more than 300 seconds, the passive avoidance reaction time was determined to be 300 seconds.

3) Y-maze test

The Y-maze evaluated the spontaneous alternating behavior.

The Y-maze is composed of three channels shaped like an English Y. At the end of the passage, the mouse head was faced and moved freely in the three passages for eight minutes. The number of crossings was assumed to be one crossing when mice passed three passages in a row. Spontaneous crossover behavior was calculated as a percentage of the number of crossovers and the number of arm entries through the passage.

Example 1 Preparation of Turmeric Extract

2 L of 80% methanol was added to 1 kg of finely divided turmeric roots, and the extraction was repeated twice at 40 ° C. for 2 hours in an aqueous solution. The extracts were collected, water was evaporated from methanol using a reduced pressure reflux condenser, and then dried completely with a reduced pressure drier to obtain about 300 g of turmeric extract.

Example 2 Prevention Effect of Dementia of Turmeric Extract

Fifty mice aged 4-5 weeks (20-25 g body weight) were divided into five groups, A, B, C, D and E, with 10 animals in each group. The turmeric extract obtained in Example 1 was ingested for 4 weeks instead of water to the mice of groups C and D at concentrations of 10 mg / kg and 30 mg / kg, respectively. In group E, 15 mg / kg of ferulic acid, the curcumin monomer in turmeric extract, was used. Concentrations were given to the mice, and mice in groups A and B were fed with normal water for 4 weeks. After that, a manual avoidance test was performed. A group of mice that did not receive turmeric extract was treated with 1.85 ㎍ of beta amyloid (42-1), which does not cause dementia, as a control group, and dementia was applied to the other B, C, D, and E mice. Dementia was induced by administering 1.85 μg of beta amyloid (1-42) into the ventricle. After performing intraventricular injection as described above, the manual hedging test was performed and the average value was obtained from 10 mice, and the results are shown in FIG. 2.

As shown in FIG. 2, the beta amyloid (1-42) alone group (Group B) significantly reduced the passive avoidance response time compared to the control group (P <0.05), but the turmeric extract was 10 mg / kg (0.08%). In the group administered with 30 mg / kg (0.1%) concentration (C and D), the passive avoidance reaction time was increased compared to the beta amyloid (1-42) group (P <0.05).

In addition, 1, 2, 3, 4 weeks after the administration of turmeric extract, beta amyloid was administered to perform the Y-maze test and calculate the amount of cross activity. As shown in FIG. 4, the beta amyloid (1-42) -only group (group B) reduced the cross-activity amount compared to the control group (group A), whereas the group administered prophylactically with turmeric extract (C, D, E). And group F), the cross activity was increased.

Therefore, from these results it was confirmed that turmeric extract is an effective material for the prevention and treatment of dementia.

Example 3 Separation of Curcumin and Confirmation of Dementia Prevention Effect

In order to purify the turmeric extract separated in Example 1 to a purity of 90% or more, the material was separated by thin layer chromatography. Each fraction was separated by UV absorbance measurement to obtain a UV profile, and then stored at low temperature by combining the same absorbance.

Subsequently, the chemical structure was analyzed by performing HPLC (High performance liquid chromatography) analysis by selecting a material having a large absorbance among the materials. It was confirmed that it contains curcumin (Curcumin) and various other types of ingredients as the main component. HPLC analysis conditions at this time were as follows, and the analysis results are shown in FIG.

Column: Reversed-ODS column (7 μm, 250 mm × 4 mm);

Eluent: acetonitrile: water = 48: 52

Flow rate: 1.0 ml / min

Detector: UV detector (wavelength 425 nm)

The dementia prevention effect of curcumin, the main active ingredient separated by the thin layer chromatography, was confirmed as follows.

As in Example 2, 50 4-5 week old mice (20-25 g body weight) were divided into five groups, A, B, C, D and E, 10 by each group. The curcumin is ingested at 2 mg / kg and 5 mg / kg, and ferulic acid at 15 mg / kg for 4 weeks instead of water to mice in groups C, D and E, and is usually used in groups A and B. Was fed for 4 weeks. Afterwards, 1.85 μg of beta amyloid (42-1) was given to group A mice without curcumin, and 1.85 μg of beta amyloid (1-42) was given to mice of group B, C, D, and E. Administration in the ventricles. After the intraventricular injection, a manual evasion test was performed to obtain an average value in 10 rats, and the results are shown in FIG. 3.

As shown in Figure 3, the group administered only beta amyloid (1-42) (group B) significantly reduced passive avoidance time compared to the control group. However, in the experimental groups (C, D and E group) administered curcumin prophylactically for 4 weeks, the dose-dependent reduction of the passive avoidance time was prevented to confirm the curcumin dementia preventive effect.

Therefore, from these results it was confirmed that curcumin component in turmeric extract is effective in preventing and treating dementia.

Example 4 Confirmation of Curcumin Brain Cell Protection

Sixty four to five week old mice (20-25 g body weight) were divided into six groups, A, B, C, D, E, and F, with 10 animals in each group. Among them, curcumin was ingested at 100 μM for 4 weeks, and mice in groups A, B, D, and F were fed with normal water for 4 weeks. After that, beta amyloid (42-1) was given to mice of group A and D (control) that did not receive curcumin, and beta amyloid (1-42) to mice of group B, C, E and F, respectively. Each dose was administered intraventricularly.

One day after beta amyloid administration, the mice were anesthetized with sodium pentobarbital, the abdomen of the anesthetized mice was excised, and then fixed by perfusion of 4% paraformaldehyde into the left ventricle, followed by cutting the brain. After making slices from the brain cut according to Cho et al ., J. Comp. Neurol ., 369: 264-276, 1996, the OX-42 antibody (Halan (Sera-Lab)) was prepared. The solution diluted 1: 500 was immunochemically stained for OX-42 of the pyriform cortex and amygdaloid nucleus. The flakes were then observed at 200 and 400 times magnification under an upright microscope (see Figure 5). The OX-42 staining method is used to diagnose Alzheimer's disease as a method of staining microglia, which are increased in brain cells during virus infection, using an antibody against microglia.

As shown in FIG. 5, in the group in which only beta amyloid (1-42) was injected (groups B and E), the degree of OX-42 staining was significantly increased in comparison with the control group, but beta amyloid (1-42) was administered after curcumin administration. In the injected group (C and F group), the degree of OX-42 staining was significantly reduced.

Therefore, it was confirmed that curcumin protects brain cells from these results.

Example 5 Curcumin Neuronal Damage Prevention Effect

According to the method described above (Wie et al ., Neurosci. Lett ., 225: 93-96, 1997), the glial cells were cultured from the cerebral cortical cells of the mouse, and then the cerebral neurons of the mouse were cultured using the substrate. .

After dividing the nerve cell culture prepared as above into five groups of A, B, C, D and E, group A was treated with beta amyloid 42-1 (control), B, C, D and Group E was treated with beta amyloid (1-42) at a concentration of 25 μM to induce dementia. Among the C, D and E groups, curcumin was treated at concentrations of 1, 10, and 100 μM, respectively, 30 minutes before the beta amyloid was administered.

The degree of nerve cell damage was determined by measuring the concentration of lactate dehydrogenase (LDH) secreted from the cultured cells into the extracellular culture medium according to the method described above. The culture was taken and the concentration of LDH secreted from cells damaged and destroyed by beta amyloid administration with a microplate reader was measured.

As a result, as shown in Figure 7, the beta amyloid-administered group (Group B) decreased LDH secretion compared to the control group (Group A), but the beta amyloid and curcumin-administered group (C, D and E groups) significantly lower LDH secretion Increased. Therefore, from these results it can be confirmed that curcumin inhibits the damage of neurons by beta amyloid (1-42).

<Example 6> Formulation of hard capsules and tablets containing turmeric extract

The turmeric extract prepared in Example 1 was prepared as a powder, and the turmeric extract powder was prepared as a hard capsule as shown in Table 1 below.

ingredient Content (% by weight) Turmeric Extract Dry Powder 57 Vitamin c 3 Microcrystalline cellulose 40 Sum 100

The hard capsule of the above was good in particle size, fluidity, fillability and the like.

In addition, as a result of preparing a tablet with microcrystalline cellulose for direct hitting, lactose for direct hitting, and white sugar for direct hitting, based on the content of the above ingredients, the hardness and sufficient disintegration degree of about 4-6 minutes are achieved even with the above ingredients and contents. Visible tablets could be prepared, and the tablets using direct sugars, which were attempted to develop chewing tablets, could be taken without any burden on taste or irritation even if they were chewed and taken without water.

Example 7 Formulation of Turmeric Extract-Containing Liquids

Turmeric extract dry powder and other ingredients were mixed in the amounts shown in Table 2 to prepare a suspension.

ingredient Content (% by weight) Turmeric Extract Dry Powder 40 Edible alcohol 2 Carboxymethyl Cellulose 1.5 Betacyclodextrin 1.0 Sweetener (erythritol) 2.0 Surfactant (twin-80) 0.5 Vitamin c 3.0 Liquid vanilla flavor 1 drop Distilled water 50 Sum 100

Suspensions prepared with the above components and contents were maintained at a stable state without separation of the layer for 1 month at room temperature, it was confirmed that the curcumin content after one month also did not change compared to the initial.

As described in detail above, the present inventors extracted curcumin from turmeric and used it as a composition for preventing and treating dementia. The composition consisting of the curcumin and derivatives thereof showed a great effect on the prevention of dementia, it can be usefully used in the treatment of dementia in the future.

Claims (12)

A composition for preventing and treating dementia comprising curcumin represented by Formula 1 or a derivative thereof and a pharmaceutically acceptable salt thereof. <Formula 1> The method of claim 1, wherein the curcumin derivative is yakuchinone A, yakuchinone B, tetrahydrocurcumin, hydroxycinnamic acid derivatives or their in vivo metabolite composition for preventing and treating dementia. 3. The composition for preventing and treating dementia according to claim 2, wherein the hydroxycinnamic acid derivative is ferulic acid, isoferulic acid, chlorogenic acid or caffeic acid. 3. The composition for preventing and treating dementia according to claim 2, wherein the metabolite in vivo is dimethoxycurcumin or bisdimethoxycurcumin. The method for preventing and treating dementia according to claim 1, wherein the curcumin or a derivative thereof is extracted from a plant. 6. The composition for preventing and treating dementia according to claim 5, wherein the plant is selected from the group consisting of turmeric, turmeric, horseradish, sessile and sprouts. A composition for preventing and treating dementia comprising 30-70 wt% of turmeric extract, 3-30 wt% of antioxidant, and 20-40 wt% of excipient or diluent. 2-70 wt% turmeric extract powder, 1-10 wt% edible alcohol, 0.5-3 wt% excipient or diluent, 0.5-3 wt% betacyclodextrin, 0.5-5 wt% sweetener, 0.1-1 wt% surfactant A composition for preventing and treating dementia comprising 0.5-5% by weight of antioxidants, 0.001-1% by weight of perfume and 25-70% by weight of distilled water. 8. The composition for preventing and treating dementia according to claim 7, wherein the antioxidant is selected from the group consisting of vitamin C, vitamin E and mixtures thereof. The method of claim 7, wherein the excipient or diluent is lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphonate, calcium silicate, cellulose , Methyl cellulose, ethyl cellulose, microcrystalline cellulose, carboxymethyl cellulose, hydroxypropyl methyl cellulose, hydroxypropyl methyl cellulose phthalate, polyvinylpyrrolidone, water, methyl hydroxybenzoate, propyl hydroxy benzoate, talc, magnesium A composition for preventing and treating dementia, characterized in that it is selected from the group consisting of stearate, light silicic anhydride and mineral oil. 8. The composition for preventing and treating dementia of claim 7, wherein the composition further comprises a filler, an anticoagulant, a lubricant, a humectant, a perfume, an emulsifier, or a preservative. Food for preventing and treating dementia comprising curcumin or a derivative thereof and a pharmaceutically acceptable salt thereof. <Formula 1>